Adult HBV Vaccination: Overcoming Gaps to Lessen the Burden and Impact of HBV

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Fibronostics, Fujifilm/Wako, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, Hepatx, HepQuant, Intercept, Janssen, Merck, Perspectum, Pfizer, Quest, Sonic Incytes, and Topography Health, and Venatorx; has served on advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer and Prodigy; serves on current clinical trials alliance for Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect; serves on speakers bureaus for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; and has stock options with Eiger, Genlantis, HepQuant, AngioCrine, HepaTx.